Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 28 | 2026 | 600 | 8.200 |
Why?
|
| Lewy Body Disease | 14 | 2026 | 33 | 7.020 |
Why?
|
| Cognitive Dysfunction | 12 | 2025 | 464 | 3.870 |
Why?
|
| Sex Characteristics | 10 | 2026 | 791 | 3.750 |
Why?
|
| Alzheimer Disease | 10 | 2026 | 622 | 2.830 |
Why?
|
| Supranuclear Palsy, Progressive | 4 | 2025 | 18 | 1.860 |
Why?
|
| Prodromal Symptoms | 2 | 2025 | 21 | 1.820 |
Why?
|
| Tauopathies | 3 | 2026 | 17 | 1.730 |
Why?
|
| Neuropsychological Tests | 16 | 2025 | 1137 | 1.320 |
Why?
|
| Sexual and Gender Minorities | 2 | 2024 | 251 | 1.210 |
Why?
|
| Neurodegenerative Diseases | 2 | 2023 | 151 | 1.170 |
Why?
|
| Lewy Bodies | 4 | 2024 | 10 | 1.020 |
Why?
|
| Movement Disorders | 3 | 2025 | 70 | 0.880 |
Why?
|
| Brain | 8 | 2026 | 2941 | 0.840 |
Why?
|
| Frontotemporal Dementia | 4 | 2025 | 57 | 0.820 |
Why?
|
| Aged | 28 | 2026 | 25947 | 0.760 |
Why?
|
| Dementia | 2 | 2026 | 304 | 0.740 |
Why?
|
| Cognition | 7 | 2025 | 1269 | 0.720 |
Why?
|
| Frontotemporal Lobar Degeneration | 3 | 2026 | 19 | 0.660 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 301 | 0.650 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2020 | 20 | 0.650 |
Why?
|
| Activities of Daily Living | 1 | 2024 | 441 | 0.650 |
Why?
|
| Language | 3 | 2020 | 323 | 0.640 |
Why?
|
| Memory, Short-Term | 2 | 2020 | 271 | 0.640 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 46 | 0.630 |
Why?
|
| Humans | 58 | 2026 | 144957 | 0.620 |
Why?
|
| Neural Pathways | 3 | 2023 | 311 | 0.620 |
Why?
|
| Myoclonus | 1 | 2019 | 17 | 0.610 |
Why?
|
| Cognitive Aging | 1 | 2019 | 18 | 0.610 |
Why?
|
| Subthalamic Nucleus | 1 | 2020 | 83 | 0.600 |
Why?
|
| Disease Progression | 6 | 2026 | 2852 | 0.600 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2019 | 6 | 0.580 |
Why?
|
| Male | 35 | 2026 | 72406 | 0.580 |
Why?
|
| Caregivers | 4 | 2025 | 1049 | 0.570 |
Why?
|
| Female | 36 | 2026 | 78376 | 0.560 |
Why?
|
| Hydrocephalus | 1 | 2019 | 111 | 0.560 |
Why?
|
| Aged, 80 and over | 9 | 2026 | 8279 | 0.530 |
Why?
|
| Corpus Striatum | 1 | 2019 | 179 | 0.530 |
Why?
|
| Hyperkinesis | 1 | 2017 | 16 | 0.520 |
Why?
|
| Psycholinguistics | 1 | 2017 | 20 | 0.520 |
Why?
|
| Vocabulary | 1 | 2017 | 35 | 0.520 |
Why?
|
| Deep Brain Stimulation | 1 | 2020 | 213 | 0.520 |
Why?
|
| Mitochondrial Proteins | 1 | 2019 | 263 | 0.510 |
Why?
|
| Sex Factors | 5 | 2025 | 2114 | 0.510 |
Why?
|
| Dopamine | 1 | 2019 | 289 | 0.500 |
Why?
|
| Affect | 1 | 2019 | 318 | 0.490 |
Why?
|
| Longitudinal Studies | 6 | 2025 | 2947 | 0.480 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 439 | 0.470 |
Why?
|
| Gait Disorders, Neurologic | 3 | 2023 | 45 | 0.460 |
Why?
|
| Anxiety | 2 | 2019 | 1110 | 0.430 |
Why?
|
| Age of Onset | 3 | 2025 | 551 | 0.420 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2026 | 46 | 0.420 |
Why?
|
| REM Sleep Behavior Disorder | 2 | 2025 | 17 | 0.410 |
Why?
|
| Parkinsonian Disorders | 2 | 2025 | 43 | 0.400 |
Why?
|
| Middle Aged | 21 | 2026 | 35928 | 0.400 |
Why?
|
| Phenotype | 2 | 2025 | 3164 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2026 | 3869 | 0.390 |
Why?
|
| Databases, Factual | 2 | 2018 | 1486 | 0.360 |
Why?
|
| Executive Function | 4 | 2025 | 461 | 0.330 |
Why?
|
| Neurofilament Proteins | 2 | 2025 | 80 | 0.270 |
Why?
|
| Basal Ganglia | 2 | 2024 | 57 | 0.260 |
Why?
|
| Semantics | 2 | 2017 | 100 | 0.250 |
Why?
|
| Smartphone | 2 | 2024 | 102 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 2584 | 0.230 |
Why?
|
| Antiparkinson Agents | 1 | 2025 | 41 | 0.230 |
Why?
|
| Multiple System Atrophy | 1 | 2025 | 8 | 0.230 |
Why?
|
| Language Disorders | 1 | 2025 | 29 | 0.230 |
Why?
|
| Support Vector Machine | 1 | 2025 | 36 | 0.220 |
Why?
|
| White Matter | 2 | 2024 | 154 | 0.220 |
Why?
|
| Diarrhea | 1 | 2025 | 192 | 0.210 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2025 | 154 | 0.200 |
Why?
|
| Substantia Nigra | 1 | 2024 | 63 | 0.200 |
Why?
|
| Restless Legs Syndrome | 1 | 2023 | 20 | 0.200 |
Why?
|
| Atrophy | 2 | 2026 | 201 | 0.190 |
Why?
|
| Gender Identity | 1 | 2023 | 121 | 0.190 |
Why?
|
| Suicide, Assisted | 1 | 2022 | 31 | 0.170 |
Why?
|
| Disease Management | 1 | 2025 | 647 | 0.170 |
Why?
|
| Patient Selection | 1 | 2025 | 719 | 0.170 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2020 | 15 | 0.160 |
Why?
|
| Dopamine Agents | 1 | 2020 | 22 | 0.160 |
Why?
|
| Attention | 1 | 2024 | 458 | 0.160 |
Why?
|
| Brain Mapping | 2 | 2022 | 537 | 0.160 |
Why?
|
| Proteome | 1 | 2025 | 518 | 0.160 |
Why?
|
| Cohort Studies | 4 | 2025 | 5965 | 0.150 |
Why?
|
| Symptom Assessment | 1 | 2021 | 137 | 0.150 |
Why?
|
| tau Proteins | 3 | 2026 | 115 | 0.150 |
Why?
|
| Memory | 2 | 2019 | 296 | 0.150 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2020 | 146 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 1721 | 0.150 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2019 | 59 | 0.150 |
Why?
|
| Social Support | 1 | 2023 | 652 | 0.150 |
Why?
|
| Space Perception | 1 | 2019 | 83 | 0.150 |
Why?
|
| Motor Disorders | 1 | 2019 | 17 | 0.140 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 103 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 728 | 0.140 |
Why?
|
| Educational Status | 1 | 2021 | 467 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2025 | 710 | 0.140 |
Why?
|
| Prevalence | 1 | 2025 | 2836 | 0.140 |
Why?
|
| Irritable Mood | 1 | 2019 | 50 | 0.140 |
Why?
|
| Memory Disorders | 1 | 2019 | 194 | 0.140 |
Why?
|
| Suicide | 1 | 2026 | 720 | 0.140 |
Why?
|
| Mental Recall | 1 | 2019 | 222 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 5872 | 0.130 |
Why?
|
| Turkey | 1 | 2017 | 21 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 343 | 0.130 |
Why?
|
| Visual Perception | 1 | 2019 | 183 | 0.130 |
Why?
|
| Reaction Time | 1 | 2019 | 438 | 0.130 |
Why?
|
| Healthy Aging | 1 | 2018 | 40 | 0.130 |
Why?
|
| Virtual Reality | 1 | 2018 | 77 | 0.130 |
Why?
|
| Iron | 1 | 2019 | 359 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2026 | 3608 | 0.120 |
Why?
|
| Functional Laterality | 1 | 2018 | 241 | 0.120 |
Why?
|
| Psychomotor Performance | 1 | 2019 | 328 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2026 | 1358 | 0.120 |
Why?
|
| Adult | 9 | 2026 | 40506 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 886 | 0.120 |
Why?
|
| Neuroimaging | 1 | 2019 | 292 | 0.120 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 328 | 0.120 |
Why?
|
| Feeding and Eating Disorders | 1 | 2019 | 163 | 0.120 |
Why?
|
| Appendectomy | 1 | 2017 | 89 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 465 | 0.120 |
Why?
|
| Depression | 1 | 2026 | 1559 | 0.120 |
Why?
|
| Family | 1 | 2021 | 679 | 0.120 |
Why?
|
| C9orf72 Protein | 2 | 2026 | 13 | 0.120 |
Why?
|
| Genotype | 1 | 2020 | 1835 | 0.110 |
Why?
|
| Movement | 1 | 2017 | 294 | 0.110 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 302 | 0.110 |
Why?
|
| Neurons | 1 | 2024 | 1642 | 0.110 |
Why?
|
| Nerve Net | 1 | 2018 | 285 | 0.110 |
Why?
|
| Gray Matter | 2 | 2025 | 92 | 0.100 |
Why?
|
| Risk Factors | 2 | 2025 | 10792 | 0.100 |
Why?
|
| Age Factors | 1 | 2021 | 3335 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 6053 | 0.090 |
Why?
|
| Mutation | 2 | 2025 | 4099 | 0.090 |
Why?
|
| Biomarkers | 4 | 2025 | 4275 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2025 | 7997 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 1389 | 0.080 |
Why?
|
| Headache Disorders | 1 | 2010 | 19 | 0.080 |
Why?
|
| Quality of Life | 1 | 2023 | 3192 | 0.080 |
Why?
|
| Blood Patch, Epidural | 1 | 2010 | 19 | 0.080 |
Why?
|
| Intracranial Hypotension | 1 | 2010 | 62 | 0.070 |
Why?
|
| Functional Neuroimaging | 2 | 2018 | 60 | 0.070 |
Why?
|
| Gait | 2 | 2023 | 313 | 0.070 |
Why?
|
| United States | 1 | 2025 | 15988 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2026 | 2925 | 0.060 |
Why?
|
| Galantamine | 1 | 2026 | 4 | 0.060 |
Why?
|
| Rivastigmine | 1 | 2026 | 6 | 0.060 |
Why?
|
| Dementia, Vascular | 1 | 2026 | 21 | 0.060 |
Why?
|
| Gastrointestinal Motility | 1 | 2025 | 29 | 0.060 |
Why?
|
| Genes, Dominant | 1 | 2025 | 101 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 85 | 0.050 |
Why?
|
| United Kingdom | 1 | 2025 | 338 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2026 | 541 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2026 | 433 | 0.050 |
Why?
|
| Dopamine Agonists | 1 | 2023 | 42 | 0.050 |
Why?
|
| Linear Models | 1 | 2026 | 854 | 0.050 |
Why?
|
| Hallucinations | 1 | 2023 | 31 | 0.050 |
Why?
|
| Social Stigma | 1 | 2025 | 172 | 0.050 |
Why?
|
| Focus Groups | 1 | 2025 | 573 | 0.050 |
Why?
|
| Impulsive Behavior | 1 | 2023 | 146 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2024 | 196 | 0.040 |
Why?
|
| Arizona | 1 | 2021 | 81 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2025 | 1495 | 0.040 |
Why?
|
| Young Adult | 1 | 2017 | 14126 | 0.040 |
Why?
|
| Learning | 1 | 2023 | 452 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1054 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 781 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 1990 | 0.030 |
Why?
|
| Proteomics | 1 | 2025 | 1195 | 0.030 |
Why?
|
| Internet | 1 | 2023 | 700 | 0.030 |
Why?
|
| Research | 1 | 2021 | 431 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 4293 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 3415 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2018 | 538 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2118 | 0.020 |
Why?
|
| Exercise | 1 | 2022 | 2201 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2018 | 17101 | 0.020 |
Why?
|